2020 October 14: Katairo announces "Enrolement completed" in STARTT study of Remofuscin
2019 June 26: Katairo announces "First Patient Treated" in STARTT study of Remofuscin
2019 June 06 Patientinformation STARTT study Nijmegen and Leiden
2019 May 20 PatientInformation STARTT study Tuebingen
2019 May 20 PatientInformation STARTT study Southampton
2018 February 14: Stargardt-Krankheit: 6 Millionen für klinische Studie (German)
2018 February 09: Katairo receives funding for STGD POC study
2017 March 25: Katairo licenses IP rights and data from Takeda
Information on Clinical Trials
Although Katairo is preparing a phase 2 trial for Stargardt disease, it is still too early to contact the company or its partners for more details. If you are interested in receiving up-to-date information by e-mail, please register for Katairo's newsletter below.
For the purpose of being contacted by Katairo upon important news, you may provide your e-mail contact information below.